When a referring DVM asks me about our therapeutic laser protocols the first question is almost always about wattage. How many watts is your unit? The assumption is that higher wattage equals better treatment. I understand where that intuition comes from. In most clinical equipment, power output is a reasonable proxy for capability. With photobiomodulation therapy, or PBMT, that logic breaks down fast. Therapeutic laser dosing is a multivariable problem and wattage is only one variable, and not the most important one.
I have been using class IV therapeutic lasers in canine rehabilitation for over a decade. The conversations I have with veterinary colleagues and other rehabilitation technicians have pushed me to write this out clearly. This is a clinical breakdown of how dose is actually calculated, what the peer-reviewed literature supports, and where I see protocols go wrong in practice.
Why Wattage Alone Misleads You
Wattage describes power output at the laser aperture. It tells you how many joules per second the unit can deliver at the source. What it does not tell you is how many photons reach the target tissue at therapeutic depth.
A 15-watt class IV laser moved rapidly across a large treatment area for 30 seconds delivers a very different tissue dose than that same unit held in slow contact technique over a 4 cm2 area for two minutes. The power setting is identical. The dose is not even close.
The marketing around class IV lasers has leaned heavily on wattage because it is a concrete, comparable number. Class IIIb units cap at 0.5 watts. Class IV units start above that threshold and can reach 25 watts or more in current veterinary systems. The jump from class IIIb to class IV is real and clinically meaningful. The difference between a 10-watt and a 20-watt unit is far less meaningful if your technique and time variables are not controlled. I want practitioners to understand that distinction before they make purchasing decisions or protocol comparisons.
Fluence Is the Actual Dose
The correct unit of therapeutic laser dose is fluence, measured in joules per square centimeter (J/cm2). This is the number that matters at the tissue level. Fluence is calculated as power density (W/cm2) multiplied by time (seconds), and power density is power output divided by spot size.
The formula matters because it exposes every variable:
- Higher wattage increases power density only if spot size stays constant.
- A larger spot size reduces power density even at the same wattage.
- Longer treatment time increases fluence delivered to that area.
- Faster hand movement reduces fluence to any given point on the skin surface.
For canine musculoskeletal rehabilitation the target surface fluence range supported in the literature is roughly 4 to 8 J/cm2 for superficial structures and 8 to 15 J/cm2 or higher when targeting deep structures like the hip joint or lumbosacral junction in a large breed dog. These numbers are starting points, not absolutes. They require adjustment based on the tissue variables I will cover shortly.
When I document a laser treatment I always record total joules delivered, treatment area in cm2, wavelength, power setting and technique (contact vs. non-contact, scanning vs. stationary). Wattage recorded alone is essentially useless for clinical review or protocol replication.
Wavelength and the Optical Window
Wavelength determines which chromophores in tissue absorb photons and how deeply the light penetrates before being scattered or absorbed. This is the photobiology that underpins everything else about PBMT dosing.
The therapeutic optical window for tissue penetration sits between approximately 650 nm and 1100 nm. Below 650 nm, melanin and hemoglobin absorb heavily, limiting depth. Above 1100 nm, water absorption increases sharply and penetration drops off again. Within that window, longer wavelengths in the near-infrared range (810 to 980 nm) penetrate more deeply into tissue than visible red wavelengths (630 to 670 nm).
The primary mitochondrial chromophore for PBMT is cytochrome c oxidase, Complex IV of the electron transport chain. Research from Hamblin and colleagues at Harvard's Wellman Center has characterized the absorption peaks of cytochrome c oxidase at approximately 620 nm, 680 nm, 760 nm and 820-830 nm. This is why dual-wavelength units that combine a near-infrared wavelength with a red wavelength have a clinical rationale that goes beyond marketing. The two wavelengths activate different absorption peaks and may address different tissue depths simultaneously.
For deep canine targets, hip joint capsule, supraspinatus insertion, lumbosacral disc spaces, I rely primarily on wavelengths in the 900 to 980 nm range because water absorption peaks that compete with penetration are lower here relative to some other near-IR bands. For superficial wound healing or incision management, a 630 to 670 nm wavelength with its stronger effects on fibroblast activity is more appropriate.
Wavelength selection is a clinical decision. Practitioners who use a single wavelength for every indication are not optimizing PBMT delivery regardless of what their fluence calculation looks like.
How I Calculate Treatment Time in Practice
The treatment time calculation sounds intimidating but it becomes intuitive after you work through it regularly. Here is the sequence I use for every new protocol I set up.
First I identify the target tissue and estimate depth from the skin surface. A canine stifle in a Labrador Retriever at healthy body weight puts the joint capsule at roughly 1.5 to 2.5 cm. A hip joint in the same dog may sit at 3 to 5 cm depending on muscling. Depth matters because tissue absorbs and scatters photons as they travel. Clinically, a reasonable estimate is that you lose roughly 50 percent of surface fluence for every centimeter of soft tissue at near-infrared wavelengths, though this varies substantially with tissue type and pigmentation.
Second I identify the target fluence at the tissue level. If I want 6 J/cm2 at 3 cm depth in a moderately pigmented dog, I need to calculate backward to determine what surface fluence I need to deliver to achieve that.
Third I determine my treatment area. I use an acetate grid or I estimate from anatomical landmarks. Overestimating the area is a common error that results in undertreating every point within it.
Fourth the unit does most of the arithmetic if I enter the data correctly. Most class IV laser consoles in current veterinary use (Companion, LiteCure, Erchonia and others) allow you to input target joules, treatment area and power setting and will calculate time for you. The critical step is accurate area entry and correct power setting for the indication.
I also adjust technique. Contact technique with pressure over the treatment site compresses superficial tissue, reduces scatter and meaningfully improves depth delivery. For a painful joint I may use light contact or a non-contact handpiece, which requires compensating with higher surface fluence. These adjustments have to be deliberate, not guessed.
Tissue Variables That Change Everything
Even a perfectly calculated fluence number requires clinical adjustment for the individual patient in front of you. The variables that most consistently change my dosing decisions are coat density and pigmentation, body condition score and subcutaneous fat depth, presence of edema or fluid, and target tissue type.
Coat density is particularly significant in canine patients. A dense double coat on a Newfoundland or Bernese Mountain Dog can absorb or reflect a substantial percentage of incident photons before they even reach the skin. Parting the coat and applying the handpiece directly to skin whenever possible is not optional technique. It is essential for accurate dose delivery.
Skin and coat pigmentation matters because melanin is a strong absorber across the therapeutic optical window. Heavily pigmented skin absorbs more photons superficially, reducing depth delivery and also generating more heat at the skin surface. In darkly pigmented patients I reduce power density (not total joules) to manage thermal load and extend treatment time to deliver the intended fluence more slowly.
Subcutaneous fat is a significant barrier because adipose tissue has a lower water content and different optical properties than muscle or connective tissue. A dog with a body condition score of 8 or 9 out of 9 requires meaningfully higher surface fluence to achieve therapeutic dose at the joint level compared to a lean athletic dog with the same skeletal dimensions.
Edema and joint effusion actually increase photon scatter and can paradoxically require higher fluence to reach the synovium or subchondral structures below the effusion.
What the Evidence Actually Says About PBM in Dogs
I am careful about overstating the evidence base for canine PBMT because the literature is genuinely mixed and I think intellectual honesty here matters for the credibility of rehabilitation medicine as a discipline.
The mechanistic evidence for photobiomodulation at the cellular level is robust. The cytochrome c oxidase hypothesis, increased ATP synthesis, modulation of reactive oxygen species, upregulation of anti-inflammatory mediators and neurological pain gate effects are supported by in vitro and animal model research. The work of Hamblin at Wellman Center and Bjordal and colleagues in Scandinavia established much of this foundational science.
In the canine-specific literature, a frequently cited study by Looney and colleagues examined PBMT for hip osteoarthritis in dogs using objective force plate gait analysis. They found improvement in peak vertical force in the laser-treated group compared to sham treatment. This study used a specific protocol with documented wavelength and fluence, which is exactly what good PBMT research requires and what too many older studies omitted.
The World Small Animal Veterinary Association and the American College of Veterinary Sports Medicine and Rehabilitation (ACVSMR) have both acknowledged PBMT as an accepted modality in veterinary rehabilitation while noting that dosing standardization remains an active area of research. The Canine Rehabilitation Institute curriculum includes PBMT dosing as a core competency in their CCRA and CCRP pathways for this reason.
What I tell referring DVMs is this: the evidence supports PBMT as a useful adjunctive modality for pain management and tissue healing when dosed appropriately for the indication. It is not a standalone cure for osteoarthritis, nerve injury or post-surgical recovery. It is one tool in a multimodal protocol, and its effectiveness is directly tied to whether the dose at the target tissue is actually therapeutic.
Dosing Errors I See in Rehab Settings
After more than a decade working in canine rehabilitation I have seen PBMT used both very well and very poorly. The errors that concern me most are the ones that result in chronic underdosing because they create the impression that laser therapy does not work when really the tissue never received a therapeutic dose.
The most common error is rapid scanning over too large an area with inadequate time. A practitioner who sweeps a class IV laser over the entire hindquarter of a German Shepherd in 90 seconds at 8 watts has delivered photons across a massive surface area. The fluence at any individual point on that surface may be well below the threshold for biological effect. Fast movement feels productive. It is not delivering dose.
The second error is failing to part the coat. I have walked into treatment rooms where a practitioner is lasering over a thick double coat with no skin contact. The photons are being absorbed and scattered in the fur. This is not treatment.
The third error is using the same protocol for every indication. A wound healing protocol and a deep joint osteoarthritis protocol require different wavelengths, different fluence targets and different technique. Plugging every patient into the same preset undermines any claim to evidence-based practice.
The fourth error is ignoring the Arndt-Schulz principle as it applies to PBMT. Higher dose is not always better. There is a dose-response curve and there is evidence that very high fluence can inhibit the biological responses you are trying to stimulate. Overdosing is less common with class IV lasers in practice because treatment times are usually kept short, but it is a real consideration when practitioners use very high power settings with prolonged stationary application over small areas.
Therapeutic laser dosing done right requires the same rigor we apply to manual therapy, aquatic therapy progression or neuromuscular electrical stimulation parameters. It is a modality with a mechanism, a dose-response curve and a body of evidence that we are obligated to apply honestly. The wattage on the device label is not a substitute for that work.